TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Turner Syndrome~* Well documented growth rate during the previous year~* Height below the 50th percentile for the age in Dutch children~* Normal thyroid function~Exclusion Criteria:~* Any endocrine or metabolic disorder~* Growth failure due to disorders of genitourinary, cardio-pulmonary, gastro-intestinal and nervous systems, nutritional/vitamins deficiencies and chondrodysplasias~* Patients with hydrocephalus

- Gender: FEMALE
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: EXPERIMENTAL): None
- Medium dose (Type: EXPERIMENTAL): None
- High dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Pocket Echocardiography Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Adult surgical (non-cardiac) patients referred preoperatively for resting transthoracic echocardiogram~Exclusion Criteria:~• No consent or withdrawal of consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full TTE (Type: EXPERIMENTAL): Full echocardiogram.
- VScan (Type: EXPERIMENTAL): Handheld echocardiogram.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium and Asthma - Clinical Trials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* Mild to moderate persistent asthma (NAEPP 1997 revised guidelines)~* Current use of inhaled beta-2- agonists or steroid inhaler therapy only (No use of prednisone in past 3 months)~* No use of products (i.e. antacids, laxatives, supplements) containing more than 50 mg Mg daily in the last 3 months~* No current use of theophylline, leukotriene antagonists, or other systemic immunomodulating compounds~* Nonsmoker~* No concurrent pulmonary disease (pulmonary hypertension, cystic fibrosis, sarcoidosis, bronchiectasis, hypersensitivity pneumonitis, restrictive lung disease, abnormal DLCOva)~* No concurrent medical diagnoses (alcoholism, coronary artery disease, diabetes, HIV infection, chronic hepatitis, uncontrolled hypertension, chronic renal failure or a psychiatric disorder that is judged to make full participation difficult)~* Not pregnant or lactating.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Never taken oral antidiabetic drugs before~* HbA1c greater than 8.5 %~* BMI (Body Mass Index) less than or equal to 35 kg/m\^2~Exclusion Criteria:~* Known or suspected allergy to repaglinide, metformin, or any of the excipients in the medications~* Taken an investigational drug in another clinical trial within 4 weeks prior to this trial~* Impaired liver function, defined as ASAT (aspartate aminotransferase) or ALAT (alanine aminotransferase) equal to or greater than 2 times upper normal limit~* Have a clinically significant, active disease of the gastrointestinal, pulmonary, neurological, renal, genitourinary, and haematological systems~* Severe uncontrolled or untreated hypertension (sitting diastolic blood pressure (BP) equal to or greater than 100 mmHg or systolic BP equal to or greater than 180 mmHg)~* Impaired renal function~* Acute or chronic acidosis or if there are plans to have a radiographic material containing iodine~* Have a clinically significant, active cardiovascular disease, or decompensated heart failure~* Treatment with systemic corticosteroids within the past two months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Repaglinide + metformin (Type: EXPERIMENTAL): Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
- Repaglinide (Type: ACTIVE_COMPARATOR): Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral primary TKA with underlying diagnosis of osteoarthritis.~* ASA I - III~* Spinal anesthesia~* All patients will have cemented total knee utilizing a medial parapatellar approach including patellar resurfacing. A tourniquet will be used in all cases~* Male and Female over 18 who are willing and able to provide informed consent~Exclusion Criteria:~* Opioid use within 3 months preoperatively~* Inability to take the protocol medications~* Anticoagulant other than aspirin~* Contraindication to regional anesthesia~* Non-english speaking~* ASA IV or greater~* Psychiatric or cognitive disorders~* Allergy/contraindications to protocol medications.~* Renal insufficiency with Cr \> 2.0 or hepatic failure~* General anesthesia~* Sensory/motor disorder involving the operative limb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Opioid Regimen (Type: ACTIVE_COMPARATOR): Weeks 1-4~* Oxycodone 5 mg PRN q4h (30 tablets)~* Tramadol 50 mg PRN q6h (30 tablets)
- Multimodal pain regimen with PRN opioids (Type: EXPERIMENTAL): Weeks 1-4~* Tylenol 1000 mg q8h (standing)~* Meloxicam 15 mg qD (standing).~* Gabapentin 200 mg BID (with morning and evening Tylenol dose)~* Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)~* Esomeprazole 20mg daily if not already on another H2 blocker or PPI~* Oxycodone 5 mg PRN q4h (30 tablets)~* Tramadol 50 mg PRN q6h (30 tablets)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin with or without other LMT, both at stable dose for at least 4 weeks prior to screening visit (Week -3).~Exclusion criteria:~* Aged \<18 years or legal age of adulthood, whichever was greater.~* Participants without established CHD or CHD risk equivalent.~* LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with a history of documented cardiovascular disease.~* LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants without a history of documented cardiovascular disease.~* Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the screening visit (Week -3) or between screening to randomization visits.~* Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.~* Atorvastatin, rosuvastatin or simvastatin was not taken daily or not taken at a registered dose.~* Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg.~* Fasting serum triglycerides \>400 mg/dL (\>4.52 mmol/L) at the screening period.~The above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
- Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Type: PLACEBO_COMPARATOR): Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Severe alcoholic hepatitis patients \[Maddrey's score \> 32\] aged between 18 to 65 years.~Exclusion Criteria:~* Presence of active infections~* Acute GI bleed~* Hepatorenal syndrome~* Patient unwilling~* DF\>120~* Autoimmune hepatitis~* Hepatitis B, Hepatitis C, HIV cases~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
- G-CSF (Type: EXPERIMENTAL): G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to enter the study, each patient must comply with the following inclusion criteria:~* Provide written informed consent and aged between 18 and 75 years of age.~* Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.~* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.~* Able and agrees to remain off prior antipsychotic medication for the duration of study.~* Good physical health on the basis of medical history, physical examination, and laboratory screening.~* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.~Exclusion Criteria:~* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.~* Any chronic organic disease of the CNS (other than schizophrenia)~* Used investigational compound within 30 days.~* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone 40mg (Type: EXPERIMENTAL): None
- Lurasidone 80mg (Type: EXPERIMENTAL): None
- Lurasidone 120mg (Type: EXPERIMENTAL): None
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA ≥10\^4 IU/mL at screening~* Confirmed chronic HCV genotype 1 or 3 infection~* HCV treatment naive~* Approximately 30% of individuals may have compensated cirrhosis at screening~Exclusion Criteria:~* Any other chronic liver disease~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Current or prior history of clinical hepatic de-compensation~* Contraindication to RBV therapy, e.g., history of clinically significant hemoglobinopathy (sickle cell disease, thalassemia).~* Chronic use of systemically administered immunosuppressive agents~* History of solid organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV 16 weeks (Type: EXPERIMENTAL): Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
- Sofosbuvir+RBV 24 weeks (Type: EXPERIMENTAL): Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Spondylarthropathy~* Heel enthesitis refractory to standard treatment~* Between 18 and 70 years of age~* The patient global assessment of the disease activity (measured by a 100 mm VAS) must be \>40 in the last 48 hours~Exclusion criteria~* Use of \> 1 local steroid injection within 2 weeks of screening~* Prior exposure to any TNF-inhibitor, including etanercept~* Dose of NSAIDs changed within two weeks of study drug evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 2 that has required daily inhaled corticosteroid in the low dose range OR LTRA as monotherapy for at least 30 days prior to Visit 2.~* Has a morning clinic pre-bronchodilator FEV1 measured at least 6 hours after the last dose of inhaled short acting beta agonist of greater than or equal to 70% and less than or equal to 95% of predicted normal~* Demonstrated reversibility of FEV1 of ≥12% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist OR has a documented reversibility of ≥ 12 % within 12 months prior to Visit 2.~Exclusion Criteria:~* Has been hospitalized at least once or required emergency treatment (was seen in the emergency room or had an urgent care visit) more than once for an asthma-related condition during the 6 months prior to Visit 2~* Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 2

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
- 2 (Type: PLACEBO_COMPARATOR): Placebo pMDI 2 inhalations bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has a complaint of sore throat.~2. If the patient is a female of childbearing potential, she has been using effective contraception since the last date of menses and is not breast-feeding or lactating.~3. If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy.~4. The patient has provided written informed consent prior to any study-related procedures.~Exclusion Criteria:~1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing clinically significant upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week).~2. The patient has a history of any hepatic disease or renal dysfunction.~3. The patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- flurbiprofen 8.75 mg lozenge (Type: EXPERIMENTAL): Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
- Placebo lozenge (Type: PLACEBO_COMPARATOR): Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with atrial fibrillation (AF) anytime in the baseline period or on the index date, also have definitive diagnosis of AF anytime in the baseline period, on the index date, or post-index period.~* Prescribed apixaban or warfarin on or after the day of AF diagnosis. The first observed prescription will be used to identify the patient's index date and treatment cohort~* No use of the any oral anticoagulants (OACs) during the baseline period (the 180 days before the index date)~* Age of 18 years or older on the index date~Exclusion Criteria:~* Having a diagnosis of valvular atrial fibrillation, post-operative atrial fibrillation, rheumatic atrial fibrillation or mechanical-valvular atrial fibrillation during the baseline and post-index period~* Having a procedure of prosthetic heart valve during the baseline period~* Having a cardiac surgery procedure record during the baseline period~* Having a diagnosis of venous thromboembolism during the baseline period~* Having a hemodialysis during the baseline period~* Female patients with pregnancy during the baseline and follow-up period~* Patients prescribed apixaban other than approved daily dose (\<5 mg or \>10 mg)~* Patients prescribed OACs during baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Injection Therapy in Patients With Lateral Epicondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. aged 20-60 years,~2. had a clinical diagnosis of lateral epicondylitis, defined as pain over the lateral humeral epicondyle of at least 6 months' duration,~3. provoked by palpation and resisted wrist/middle finger extension or gripping,~4. participants needed to score at least 30/100 on Visual analogue scale (VAS),~5. be able to understand enough Turkish to complete the outcome questionnaire.~Exclusion Criteria:~1. Any treatment for their elbow pain by a health care practitioner within the preceding 6 months,~2. Concomitant neck or other arm pain causing disability or requiring treatment within the last 6 months,~3. Clinical evidence of other primary sources of lateral elbow pain,~4. Upper limb fractures within the preceding 10 years,~5. Prior elbow surgery~6. Elbow steroid injection in the past 3 months~7. Systemic inflammatory disorder or malignancy,~8. Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Hyaluronic acid injection group (Type: EXPERIMENTAL): This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
- Prolotherapy injection group (Type: ACTIVE_COMPARATOR): This is the control group in whom prolotherapy injection was given at lateral epicondyle site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete